Healius Limited (ASX:HLS)

Market Cap	519.19M
Revenue (ttm)	1.79B
Net Income (ttm)	-22.80M
Shares Out	726.13M
EPS (ttm)	-0.03
PE Ratio	n/a
Forward PE	n/a
Dividend	0.41 (55.07%)
Ex-Dividend Date	May 9, 2025

Volume	1,430,870
Average Volume	8,685,832
Open	0.7200
Previous Close	0.7150
Day's Range	0.7200 - 0.7500
52-Week Range	0.6950 - 1.8600
Beta	0.40
RSI	28.24
Earnings Date	Aug 21, 2025

About Healius

Healius Limited provides specialty diagnostic services to consumer and practitioners in Australia. The company operates through three segments: Pathology, Imaging, and Others. It offers diagnostic imaging services, private medical laboratory, and pathology services. The company provides services under the Laverty Pathology, Dorevitch Pathology, QML Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetnostics, QML Pathology, TML Pathology, Abbott Pathology, IQ, Pathology, Kossard, Gastrolab, and Agilex Biolabs brands. It operates medi...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1994
• Employees: 9,658
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: HLS

Financial Performance

In 2024, Healius's revenue was 1.75 billion, an increase of 2.30% compared to the previous year's 1.71 billion. Losses were -645.80 million, 75.6% more than in 2023.